International Drug Company Professionals Can Earn Large Rewards By Anonymously Exposing Bribery Schemes in Pharmerging Markets by International Drug Company Whistelblower Reward Lawyer Jason S. Coomer
International whistleblowers can recover large amounts of money for exposing international medicine procurement kickbacks, medicine supply chain bribes, and other violations of the Foreign Corrupt Practices Act. As such, pharmaceutical representatives, international drug executives, government officials, physicians, health care providers, community activists, and other persons, who are the original source of specialized knowledge of international drug company bribes, international pharmaceutical company illegal kickback schemes, public health medicine procurement bribery schemes, and other illicit payments for drug procurement, medical device procurement, medication, pharmaceutical, and medical equipment contracts.
For more information on this topic, please go to the following web pages: International Medicine Procurement Bribe Whistleblower Rewards and International Government Procurement Bribe Bounty Actions.
U.S. Foreign Bribery Penalties Of Tens of Millions of Dollars for Drugmakers Need to Be Increased To Prevent Continued Foreign Corrupt Practices Act Violations
Global drugmakers are paying tens of millions of dollars to settle U.S. allegations that they bribed their way across emerging markets, but harsher penalties may be needed to deter the practice in untapped regions where billions are at stake.
Federal authorities have cast a wide net to weed out suspected gift-giving and kickbacks to foreign doctors and government officials to gain a foothold in burgeoning new markets in Asia, Eastern Europe and Latin America.
At least eight of the world's top 10 drugmakers, including Bristol-Myers Squibb Co, Pfizer Inc and Johnson &, have disclosed U.S. probes under the 1977 Foreign Corrupt Practices Act (FCPA).
Pfizer agreed to pay $60 million this year to settle FCPA charges and J&J reached a $70 million settlement last year. Pfizer is on track to record $10 billion in sales from emerging markets this year, while J&J said Brazil, Russia, India and China accounted for just under 10 percent of the $65 billion in sales it reported last year.
Analysis: U.S. foreign bribery penalties for drugmakers may lack bite | Reuters